Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

The Ras Gene02:38

The Ras Gene

7.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

5.6K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.6K
Abnormal Proliferation02:23

Abnormal Proliferation

5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

8.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.

JCO precision oncology·2026
Same author

Emerging roles of ferroptosis in modulating the immune landscape of glial tumours.

Nature cell biology·2026
Same author

MiR-940 Suppresses Ferroptosis by Controlling Expression of Key Regulatory Genes.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

GPX4 regulates lipid peroxidation and ferroptosis of stored red blood cells.

Blood. Red cells & iron·2026
Same author

Electroporation-Induced Gastric Cancer Models Through Epithelial-Specific Genetic Modifications.

Gastro hep advances·2026
Same author

Dissecting Polypharmacology in Phenotypic Screening to Resolve Ferroptotic and Necrotic Cell-Death Mechanisms.

ACS medicinal chemistry letters·2026

相关实验视频

Updated: Mar 7, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

多价小分子泛RAS抑制剂

Matthew E Welsch1, Anna Kaplan2, Jennifer M Chambers2

  • 1Department of Chemistry, Columbia University, New York, NY 10027, USA.

Cell
|February 25, 2017
PubMed
概括
此摘要是机器生成的。

研究人员开发了一种针对RAS蛋白的新型小分子,在临床前模型中显示出抗瘤活性. 这种泛RAS抑制剂显示出作为一种新的癌症治疗策略的潜力.

关键词:
一个GTPase其他克拉斯美国美国癌症化学生物学药物设计多价值的小分子

更多相关视频

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

相关实验视频

Last Updated: Mar 7, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

科学领域:

  • 医学化学
  • 癌症学
  • 分子生物学

背景情况:

  • 蛋白与蛋白相互作用 (PPI) 在细胞信号传递中至关重要,它们的破坏具有治疗潜力.
  • RAS蛋白质是细胞生长的关键调节剂, 它们的致癌突变驱动许多癌症.
  • 针对RAS效应因子与小分子的相互作用是癌症治疗的一个有前途的策略.

研究的目的:

  • 设计和合成针对瘤性RAS蛋白的新型小分子.
  • 评估这些泛RAS配体的结合亲和力和细胞效应.
  • 在临床前癌症模型中评估化合物的治疗潜力.

主要方法:

  • 基于结构的小分子设计,针对瘤性KRAS的相邻部位.
  • 潜在的泛RAS配体的合成和表征.
  • 使用微尺度热泳,NMR和ITC对化合物结合的生物物理验证.
  • 细胞死亡率和代谢稳定性的评估.
  • 在异种移植小鼠模型中评估抗瘤活性.

主要成果:

  • 一种化合物3144通过多种生物物理技术证明与RAS蛋白结合.
  • 在RAS依赖的癌细胞中,化合物3144诱导致死性.
  • 该化合物在肝脏显微体中表现出代谢稳定性.
  • 在异种移植小鼠癌症模型中观察到显著的抗瘤活性.

结论:

  • 在某些癌症中,泛RAS抑制是可行的治疗策略.
  • 使用基于结构的方法设计的多价抑制剂可以有效地向蛋白质表面.
  • 针对RAS蛋白的小分子有望成为未来的癌症治疗方法.